Details for New Drug Application (NDA): 021492
NDA 021492 describes ELOXATIN, which is a drug marketed by Sanofi Aventis Us and is included in two NDAs. Additional details are available on the ELOXATIN profile page.
The generic ingredient in ELOXATIN is oxaliplatin. There is one drug master file entry for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
The generic ingredient in ELOXATIN is oxaliplatin. There is one drug master file entry for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
Summary for 021492
| Tradename: | ELOXATIN |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | oxaliplatin |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Aug 9, 2002 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Aug 9, 2002 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
